Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. on December 23, 2009. The filing reports the entry into a material definitive agreement regarding the company's corporate headquarters lease.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the lease amendment:
- Lease Extension Term: 8 months (June 1, 2010, through January 31, 2011).
- Monthly Base Rent: $4,442.20 during the extension term.
- Leased Space: Approximately 3,173 rentable square feet (Suite 100, 6725 Mesa Ridge Road, San Diego, CA).
Material Changes
The company executed a Third Amendment to its Standard Multi-Tenant Office Lease. This amendment extends the lease term, which was originally set to expire on May 31, 2009, by an additional eight months. The filing does not disclose other material changes to operations or financial position.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the obligation to pay rent under the amended lease terms. The document notes that the description of the amendment is qualified by the full text of the agreement attached as Exhibit 10.1.
Investor Verification Checklist
- Verify the total cost of the 8-month extension ($4,442.20 x 8) against the company's current cash position.
- Confirm if the "Gross" lease structure requires the company to pay additional operating expenses beyond the base rent.
- Review the full text of Exhibit 10.1 for any termination clauses or additional obligations not summarized in the 8-K.
- Note the discrepancy between the request metadata ("Savara Inc") and the filing registrant ("ADVENTRX Pharmaceuticals, Inc").